ArticleAmerican journal of translational research2019
Efficacy of subcutaneous immunotherapy in a mouse model of Humulus pollen-induced allergic asthma.
Article in American journal of translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- Establishment and characterization of murine models of asthma and subcutaneous immunotherapy for Humulus pollen allergy.Immunity, inflammation and disease · 2021Article
- Artemisia sieversiana pollen allergy and immunotherapy in mice.American journal of translational research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to evaluate the therapeutic effect of subcutaneous injection of high-dose of Humulus pollen allergen on a mouse model of allergic asthma.
methodHumulus pollen-sensitized mice received either regular subcutaneous injections of Humulus pollen allergen extract or control treatment were sacrificed. Airway responsiveness, pulmonary inflammatory cell infiltration, serum cytokine secretion and serum immunoglobulin E (IgE) and G2a (IgG2a) levels were measured.
resultOur results showed that subcutaneous immunotherapy with high-dose of Humulus pollen allergen could obviously relieve the symptoms and improve the pulmonary function in mice with allergic asthma. It also elevated serum IgE and IgG level compared with model group. The Humulus pollen allergens could be identified in serum and the molecular weight of serum proteins that had the maximum binding to allergen were ~25 kDa and ~38 kDa in 7 cases (70%) and 6 cases (60%), respectively.
conclusionSubcutaneous immunotherapy (high-dose) could effectively alleviate airway hyperresponsiveness and reduce airway inflammatory infiltration in allergic asthmatic mice.
Indexed as
Identifiers
30787986PMC6357336W2983030136What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.